sulfaphenazole has been researched along with Breast Cancer in 3 studies
Sulfaphenazole: A sulfonilamide anti-infective agent.
sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h." | 1.37 | Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ( Jo, I; Jones, DR; Khanna, M; Knabe, WE; Li, J; Li, L; Meroueh, SO; Nakshatri, H; Oh, K; Pollok, KE; Sandusky, GE; Silver, JM; Sinn, AL; Sledge, GW; Wang, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, F | 1 |
| Li, J | 1 |
| Sinn, AL | 1 |
| Knabe, WE | 1 |
| Khanna, M | 1 |
| Jo, I | 1 |
| Silver, JM | 1 |
| Oh, K | 1 |
| Li, L | 1 |
| Sandusky, GE | 1 |
| Sledge, GW | 1 |
| Nakshatri, H | 1 |
| Jones, DR | 1 |
| Pollok, KE | 1 |
| Meroueh, SO | 1 |
| Sun, Y | 3 |
| Wang, L | 1 |
| Wu, T | 1 |
| Yin, W | 1 |
| Wang, J | 1 |
| Xue, Y | 1 |
| Qin, Q | 1 |
| Yang, H | 1 |
| Zhao, D | 1 |
| Cheng, M | 1 |
| Eissa, AG | 1 |
| Barrow, D | 1 |
| Gee, J | 1 |
| Powell, LE | 1 |
| Foster, PA | 1 |
| Simons, C | 1 |
3 other studies available for sulfaphenazole and Breast Cancer
| Article | Year |
|---|---|
Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.
Topics: Angiogenesis Inhibitors; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell | 2011 |
Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Design; | 2022 |
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Triazoles | 2022 |